BioAtla (BCAB)
Nasdaq Market Closed
BioAtla, Inc. is a clinical-stage biotechnology company developing antibody-based cancer therapies, with a focus on solid tumors. The company’s research platform is built around its conditionally active biologics, or CAB, technology, which is designed to create antibodies that are more active in the tumor microenvironment than in normal tissue. This approach aims to improve the therapeutic window of oncology drugs by directing activity toward cancer cells while limiting effects on healthy cells.
BioAtla’s pipeline includes antibody-drug conjugates and bispecific antibody programs. Its lead programs include mecbotamab vedotin, also known as BA3011, and ozuriftamab vedotin, also known as BA3021, both of which are designed to target tumor-associated antigens and deliver a cytotoxic payload. The company is also developing evalstotug, or BA3071, an immune-oncology candidate, along with BA3182, a CAB bispecific program targeting EpCAM and CD3, and additional bispecific antibody candidates.
As a clinical-stage company, BioAtla does not operate like a commercial pharmaceutical business with a diversified marketed product portfolio. Its activities are concentrated on discovery, preclinical work, clinical trials, regulatory strategy, manufacturing preparation, and potential commercialization of its CAB-based therapies. Success depends heavily on clinical data, safety results, regulatory progress, financing capacity, and the competitive landscape for cancer treatments.
BioAtla’s distinctive feature is its attempt to engineer selectivity into antibody therapies through tumor-condition-dependent activation. If successful, the platform could support multiple oncology assets across different tumor types and treatment mechanisms, including targeted drug delivery and immune cell engagement.
Last updated
- Market Cap
- 5.63M
- P/E
- —
- P/FCF
- —
- P/S
- 2.82
- Enterprise Value
- 3.67M
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 11085 TORREYANA ROAD, SAN DIEGO, CA, 92121
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
BioAtla to Participate in the Citizens Life Sciences Conference
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
BioAtla to Participate in the Jefferies London Healthcare Conference
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 5.63M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 3.67M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- -0.15
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 2.82
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -0.07
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.84
- EPS
- -30.55
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 135.67%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -590.91%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 0.15
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.15
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.09
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 32.12K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 3.4
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | 2M | — | — | — |
| Gross profit | — | 2M | — | — | — |
| Operating income | -9.31M | -9.26M | -13.79M | -18.65M | -17.61M |
| EBITDA | -9.19M | -9.24M | -13.73M | -18.53M | -17.43M |
| Net income | -6.34M | -9.78M | -15.78M | -18.71M | -15.33M |
| Basic EPS | -4.22 | -8 | -13.5 | -16 | -13.16 |
| Diluted EPS | -4.22 | -8 | -13.5 | -16 | -13.16 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 8.57M | 13.83M | 15.91M | 27.13M | 38.29M |
| Total liabilities | 45.88M | 50.02M | 47.15M | 43.87M | 37.74M |
| Total equity | -37.31M | -36.19M | -31.24M | -16.75M | 547K |
| Cash & equivalents | 1.96M | 7.12M | 8.32M | 18.21M | 32.36M |
| Current assets | 3.09M | 8.01M | 9.67M | 20.61M | 37.54M |
| Current liabilities | 20.69M | 21.92M | 17.98M | 16.6M | 16.01M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -5.27M | -7.92M | -9.88M | -14.12M | -16.29M |
| Investing cash flow | — | — | — | — | — |
| Financing cash flow | 110K | 6.71M | -6K | -36K | -395K |
| Change in cash | -5.16M | -1.2M | -9.89M | -14.16M | -16.68M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 10-Q — BioAtla, Inc. | View Filing | |
| edgar index | 10-K/A — BioAtla, Inc. | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B2 — BioAtla, Inc. | View Filing | |
| edgar index | 424B2 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — Vasquez Christian | View Filing | |
| form 4 | Form 4 — Sievers Eric | View Filing | |
| edgar index | 424B2 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| edgar index | DEFA14A — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Sievers Eric | View Filing | |
| form 4 | Form 4 — WALDRON RICHARD A | View Filing | |
| form 4 | Form 4 — Vasquez Christian | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| edgar index | DEFM14A — BioAtla, Inc. | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| edgar index | PREM14A — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-3 — BioAtla, Inc. | View Filing | |
| edgar index | DEFA14A — BioAtla, Inc. | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| edgar index | DEFA14A — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| edgar index | 4 — BioAtla, Inc. | View Filing | |
| form 4 | Form 4 — Vasquez Christian | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — SHORT JAY M PHD | View Filing | |
| form 4 | Form 4 — Sievers Eric | View Filing | |
| form 4 | Form 4 — WALDRON RICHARD A | View Filing | |
| edgar index | PRE 14A — BioAtla, Inc. | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| edgar index | 424B5 — BioAtla, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing | |
| edgar index | 10-Q — BioAtla, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — BioAtla, Inc. | View Filing | |
| edgar index | 8-K — BioAtla, Inc. | View Filing |